CClinicalTrials.gg
Sign In
CompletedNCT01449097Updated Dec 22, 2011

Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength and Mobilization in Healthy Volunteers

A Phase 4 interventional study of Adductor-Canal-Blockade and The femoral nerve block in Muscle Strength and Healthy Volunteers, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-22.

Sponsored by Rigshospitalet, Denmark · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Male
01

Study summary

The aim of this study is to investigate the efficacy of the Adductor-Canal-Blockade versus the femoral nerve block versus placebo on muscle strength in healthy volunteers. The investigators hypothesize that the Adductor-Canal-Blockade results in a lesser reduction of the quadriceps muscle strength compared to the femoral nerve block.

02

Conditions studied

  • Muscle Strength
  • Healthy Volunteers

Keywords

  • Adductor-Canal-blockade,
  • human volunteers,
  • US-guided nerve block
  • femoral nerve block
03

In context

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • written informed consent
  • ASA 1
  • BMI > 18 og \< 25

Exclusion criteria

Exclusion Criteria:

  • Can not cooperate to the exam
  • Do not speak or understand Danish
  • Drug allergy
  • Alcohol or drug abuse
  • Daily consumption of analgetics on prescription
  • Any drug intake within the last 48 hours
  • Neuromuscular defects in the femoral nere, the obturator nerve or the muscles of the thigh.
  • Previous surgery or trauma to the lower limb
  • Diabetes Mellitus
  • Intake of steroids, except steroids for inhalation
  • Physical exercise within the last 24 hours prior to Day 1 and 2 of the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Adductor-Canal-Blockade

    Procedure: Adductor-Canal-Blockade

  • Active comparator
    The femoral nerve block

    Procedure: The femoral nerve block

  • Placebo comparator
    Placebo

    Procedure: Placebo

Interventions

  • ProcedureAdductor-Canal-Blockade

    US-guided Adductor-Canal-blockade with Ropivacaine

  • ProcedureThe femoral nerve block

    US-guided femoral nerve block with ropivacaine

  • ProcedurePlacebo

    US-guided Adductor-Canal-Blockade/femoral nerve block with saline

06

What researchers measure

Primary outcomes

  1. the difference in quadriceps muscle strength between the Adductor-Canal-Blockade and placebo

    Time frame: 0-6 hours

Secondary outcomes

  1. The difference in quadriceps muscle strength between the Adductor-Canal-Blockade and the femoral nerve block

    Time frame: 0-6 hours

  2. The difference in quadriceps muscle strength between the placebo and the femoral nerve block

    Time frame: 0-6 hours

  3. The difference in adductor muscle strength between the groups

    Time frame: 0-6 hours

  4. The difference in mobilization between the groups

    Time frame: 0-6 hours

07

Study locations

1 site
  • Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet
    Copenhagen, 2100, Denmark
08

References and documents

Publications

  • Jaeger P, Nielsen ZJ, Henningsen MH, Hilsted KL, Mathiesen O, Dahl JB. Adductor canal block versus femoral nerve block and quadriceps strength: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Anesthesiology. 2013 Feb;118(2):409-15. doi: 10.1097/ALN.0b013e318279fa0b. PubMed 23241723 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01449097
Lead sponsor
Rigshospitalet, Denmark
Responsible party
Pia Jaeger (Principal investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Oct 7, 2011
Start date
Oct 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Dec 22, 2011

Study contacts

Pia Jæger, MD
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Rigshospitalet, Denmark

Start the discussion